Literature DB >> 20808559

How we treat febrile neutropenia in patients receiving cancer chemotherapy.

Gary H Lyman1, Kenneth V I Rolston.   

Abstract

Although improved supportive care has reduced mortality associated with febrile neutropenia, it continues to cause chemotherapy limitations, morbidity, mortality, and cost among patients with cancer.

Entities:  

Year:  2010        PMID： 20808559      PMCID： PMC2868641          DOI： 10.1200/JOP.091092

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  40 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.

Authors:  J Carratalà; B Rosón; A Fernández-Sevilla; F Alcaide; F Gudiol
Journal:  Arch Intern Med       Date:  1998-04-27

5.  Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002).

Authors:  Padmavati Kumashi; Essam Girgawy; Jeffrey J Tarrand; Kenneth V Rolston; Issam I Raad; Amar Safdar
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

6.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

Review 7.  Risk assessment and treatment of low-risk patients with febrile neutropenia.

Authors:  Winfried V Kern
Journal:  Clin Infect Dis       Date:  2006-01-06       Impact factor: 9.079

8.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

9.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Authors:  Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher
Journal:  J Clin Oncol       Date:  2004-09-20       Impact factor: 44.544

Review 10.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544
View more
  11 in total

1.  Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models.

Authors:  Xinsong Du; Jae Min; Chintan P Shah; Rohit Bishnoi; William R Hogan; Dominick J Lemas
Journal:  Int J Med Inform       Date:  2020-04-15       Impact factor: 4.046

2.  Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.

Authors:  Joy Bacrie; Marc Laurans; Pauline Iorio; Emmanuelle Fourme; Anne Béthune Volters; Laurence Bozec; Florence Lerebours; Coraline Dubot; Okba Bensaoula; Bilel Benzidane; Jean-Yves Pierga; Delphine Lefeuvre
Journal:  Support Care Cancer       Date:  2018-05-31       Impact factor: 3.603

Review 3.  Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

Authors:  Hisham Abdel-Azim; Weili Sun; Lingtao Wu
Journal:  Pharmacol Ther       Date:  2019-08-27       Impact factor: 12.310

4.  Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Authors:  Chris Skedgel; Daniel Rayson; Tallal Younis
Journal:  Support Care Cancer       Date:  2015-06-17       Impact factor: 3.603

Review 5.  Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.

Authors:  Tallal Younis; Daniel Rayson; Kara Thompson
Journal:  Support Care Cancer       Date:  2012-01-15       Impact factor: 3.603

6.  Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.

Authors:  Bernard L Marini; Shannon M Hough; Kevin S Gregg; Haya Abu-Seir; Jerod L Nagel
Journal:  Support Care Cancer       Date:  2015-01-10       Impact factor: 3.603

7.  Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.

Authors:  Wei Tian; Yali Wang; Yunxiang Zhou; Yihan Yao; Yongchuan Deng
Journal:  Front Oncol       Date:  2022-04-25       Impact factor: 5.738

8.  Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.

Authors:  Hazem Assi; Joshua Murray; Laura Boyle; Daniel Rayson
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

9.  Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.

Authors:  Esse I H Akpo; Irshaad R Jansen; Edith Maes; Steven Simoens
Journal:  Front Pharmacol       Date:  2017-09-13       Impact factor: 5.810

10.  Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: A timeline of clinical and microbial trends through the years.

Authors:  K Govind Babu; D Lokanatha; K C Lakshmaiah; M C Suresh Babu; Linu A Jacob; Gita R Bhat; Harsha Vardhana; Mahua Sinha; B R Vijaykumar; B G Sumati; R S Jayshree
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.